View as cardsView as table

Next-generation AAV therapies for management of intractable chronic pain

Fiscal Year Awarded:

2020

Principal Investigator:

Michael Greenberg

Target validation and in vivo testing of a broad-spectrum antiviral

Fiscal Year Awarded:

2020

Principal Investigator:

Priscilla Yang

Targeting apoptotic pathways for ALS, Alzheimer’s Disease and Parkinson’s Disease

Fiscal Year Awarded:

2020

Principal Investigator:

Bruce Bean

A novel system for rational discovery of polycystic kidney disease therapeutics

Fiscal Year Awarded:

2019

Principal Investigator:

Adrian Salic

Computationally designed therapy targeting lysosomal function and inflammation in neurodegenerative diseases

Fiscal Year Awarded:

2019

Principal Investigator:

Peter Park

Development of a new precision therapeutic for an important cancer target

Fiscal Year Awarded:

2019

Principal Investigator:

Stephen Blacklow

Development of AAV-mediated mini-gene therapy for Usher syndrome type 1F, a combined deafness and blindness

Fiscal Year Awarded:

2019

Principal Investigator:

David Corey

Development of an inexpensive at-home influenza kit and detection technology

Fiscal Year Awarded:

2019

Principal Investigator:

Michael Springer

Development of new antiviral compounds

Fiscal Year Awarded:

2019

Principal Investigator:

Donald Coen

Isoguvacine and benzodiazepine derivatives for the treatment of tactile hypersensitivity and anxiety in autism spectrum disorders

Fiscal Year Awarded:

2019

Principal Investigator:

David Ginty